Cardiol Therapeutics surprises investors with a significant earnings beat, signaling potential in the pharmaceutical sector.
Cardiol Therapeutics Inc Class A (CRDL.TO) reported its earnings on August 12, 2026, for the fiscal period ending June 30, 2026. The company posted an earnings per share (EPS) of -$0.05, surpassing analyst expectations of -$0.10, which is a remarkable 50% surprise. This marks the third earnings beat in the last four quarters, showcasing the company's improving financial performance amidst ongoing clinical developments.
Recent earnings trend
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeAdvertisement
Market cap
$289.33M
52W high
$2.69
52W low
$1.23
1W change
+20.87%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 141.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+141.0% Upside
Current Price
C$2.49
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
69.8%
Annualized
90-Day Vol
58.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.98
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.64 | C$2.08 โ C$3.36 |
| 60 trading days | C$2.80 | C$1.99 โ C$3.94 |
| 90 trading days | C$2.98 | C$1.96 โ C$4.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 3 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | โ | -0.0800 | โ |
| 2026-06-30 | 2026-08-12 | -0.0500 | -0.1000 | +50.0% |
| 2026-03-31 | 2026-05-12 | -0.0719 | -0.0900 | +20.1% |
| 2025-12-31 | 2026-03-31 | -0.0700 | -0.1100 | +36.4% |
| 2025-09-30 | 2025-11-13 | -0.1200 | -0.1000 | -20.0% |
| 2025-06-30 | 2025-08-14 | -0.1000 | -0.1200 | +16.7% |
Advertisement
Investor takeaway: Investors should note Cardiol's recent earnings performance as a positive indicator of its operational progress, especially considering its ongoing clinical trials and potential market opportunities. However, the company still operates at a loss, so careful consideration of its future growth prospects is essential.
Cardiol Therapeutics Surprises with 50% EPS Beat
With an EPS of -$0.05 against an estimate of -$0.10, Cardiol's earnings performance indicates a significant improvement in its financial trajectory.
Bull case
The positive earnings surprise shows that Cardiol is managing its costs effectively and improving operational efficiencies. The company is making strides in its clinical programs, particularly the Phase III MAVERIC trial, which could lead to significant revenue opportunities if successful. Additionally, with a bullish analyst consensus and a substantial potential upside to price targets, Cardiol presents an attractive investment opportunity.
Bear case
Despite the earnings beat, Cardiol continues to report negative EPS, highlighting ongoing financial challenges. The pharmaceutical sector is highly competitive, and the success of clinical trials is uncertain. Investors should remain cautious of potential volatility and the risks associated with drug development timelines and regulatory approvals.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
